|
|
Post by computerresearchtech on Oct 2, 2014 23:30:15 GMT -5
Picked this up off Yahoo Board... Have seen before but don't remember if was ever posted here. If you have not seen you should view and then keep the faith as it is clear what is going on with Mannkind... Why these guys are not all in jail remains a mystery to me... www.youtube.com/watch?v=c6gxPCurDJs&app=desktopThat video is so disturbing! I recommend watching this one after to put a smile on your face again: John Stewart vs Cramer: www.youtube.com/watch?v=FP3YyJz3HsU |
|
|
|
Post by mannmade on Oct 14, 2014 12:18:36 GMT -5
|
|
|
|
Post by mnholdem on Oct 14, 2014 15:02:17 GMT -5
That puts the tally of investment analysts for MNKD at:
- 6 - Buy
- 3 - Hold
- 1 - Underperform
Which investment firm has the underperform rating?
|
|
|
|
Post by dreamboatcruise on Oct 14, 2014 15:12:12 GMT -5
That puts the tally of investment analysts for MNKD at:
- 6 - Buy
- 3 - Hold
- 1 - Underperform
Which investment firm has the underperform rating?
And how long ago did they last update their opinion? |
|
|
|
Post by vissertrades on Oct 15, 2014 19:28:21 GMT -5
|
|
|
|
Post by 4Balance on Oct 15, 2014 22:28:30 GMT -5
|
|
|
|
Post by 4Balance on Oct 17, 2014 1:41:29 GMT -5
|
|
|
|
Post by mannmade on Oct 20, 2014 9:01:55 GMT -5
|
|
|
|
Post by cybergym66 on Oct 20, 2014 9:36:20 GMT -5
Goldman Sachs initiates coverage on MannKind (NASDAQ: MNKD) with a Neutral rating and a price target of $6.00. Analyst Jay Olson estimates $1.3 billion in 2020 Afrezza sales, with peak sales of $2.1 billion in 2025.
"Despite FDA approval of Afrezza and the Sanofi commercialization deal, MNKD has fallen by >50% since June. We see shares stabilizing but with limited upside based on our view of: 1) low profitability as we are 70% below 2018E consensus EPS; 2) delayed profits starting in 2018E vs. consensus reaching profitability in 2017E; 3) likely patient-driven market dynamics requiring heavy SG&A spending, and 4) challenging deal terms with Sanofi, which are complex in our view, but should become clearer with quarterly results. These factors keep us on the sidelines for now," said Olson.
The analyst went on to say, ". . . we believe Afrezza should fulfill its promise to offer an important new option for diabetics who prefer not to inject meal-time insulin. However, commercial risk remains as we see slow Afrezza uptake driven by patient demand based on our survey of 50 endocrinologists and 50 diabetes educators. We believe the patient-centric nature of Afrezza has important financial implications:
"Significant commercial opportunity in geographies where patients influence diabetes treatment decisions (e.g. the US) but limited opportunity in other markets (e.g. ex-US).
A wait-and-see attitude among healthcare professionals and payers who are relatively more concerned with safety than convenience and must be influenced by patients. Some caregivers may want to wait for long-term safety data from an FDA mandated post-marketing study looking at lung and CV safety.
Expensive promotional investments required to educate patients and reach healthcare professionals thus creating awareness and providing launch materials (e.g. starter kits) to stimulate demand."
|
|
|
|
Post by thekindaguyiyam on Oct 20, 2014 17:24:12 GMT -5
The Washington Post Cites a Prominent Role Played by Adam Feuerstein (partial post; apologies if already posted) The Washington Post zeroes in on the business practices of Adam Feuerstein who writes for TheStreet.com. The article cites several situations in which Feuerstein’s articles and Twitter tweets appear to aid the short selling pressure on the stock. Jim Cramer, the CNBC pundit, is the founder of TheStreet.com for which Feuerstein is the star columnist. In a shocking interview that he gave to Wall Street Confidential’ s Aaron Task, he lays out his strategy for manipulating stocks for short selling. You can view this interview by googling Jim Cramer Stock Manipulation or following this link. Here are some of the key takeaways from the Cramer interview in which he amazingly laid out the process that hedge funds use to manipulate stocks. In it, the host of Mad Money says he regularly manipulated the market when he ran his hedge fund. He calls it “a fun game and it’s a lucrative game.” He urges all hedge fund managers do the same. He also says behaving illegally is okay because the SEC doesn’t understand it anyway. I would urge you to listen to the entire interview, but here are some other key quotes: On falsely creating the impression a stock is under pressure due to fundamental problems when that is not the case (what he calls “fomenting”): “You can’t foment. That’s a violation… But you do it anyway because the SEC doesn’t understand it.” He adds, “When you have six days and your company may be in doubt because you are down, I think it is really important to foment.” On being balanced and truthful: “What’s important when you are in that hedge fund mode is to not be doing anything that is remotely truthful, because the truth is so against your view – it is important to create a new truth to develop a fiction,” Cramer advises that you can’t take any chances that the truth will prevail if you are positioned wrongly. Neither Cramer nor Feuerstein would speak to the Post reporter about the article. smithonstocks.com/northwest-biotherapeutics-washington-post-calls-for-investigation-of-hedge-fund-stock-trading-practices/ September 28, 2014 |
|
|
|
Post by kc on Oct 27, 2014 11:24:17 GMT -5
|
|
|
|
Post by otherottawaguy on Nov 4, 2014 9:28:09 GMT -5
GRIFFIN SECURITIES
Member FINRA, SIPC
Keith A. Markey, Ph.D., M.B.A.
Stock Symbol NASDAQ: MNKD
Current Price $5.92
12 mos. Target Price $16.25
Market Cap $2,382.1 mln
MannKind Corp. BUY
Company Update : Pharmaceuticals
Launch of Afrezza® Approaches
September financial results come in as expected. MannKind’s R&D expense for the quarter totaled $19.2 million, down 49% sequentially, and G&A costs were off 41% from the June quarter, at $19.1 million. The drop in expenditures was related to a decline in stock-based compensation performance awards, offset partly by legal expenses related to the Sanofi agreement. The downward trend should continue as Sanofi assumes more duties and MannKind focuses on building inventory. As a result, we estimate the per-share loss for the December quarter at $0.08, versus the $0.09 a share loss in the September period.
The Company has ample cash after receiving the $150 million upfront payment from Sanofi, $40 million from a debt agreement with Deerfield, and $17.3 million from warrant and stock option exercises. Another $70 million is available through Deerfield and $30 million, from The Mann Group. Also, MannKind should receive a $25 million manufacturing milestone in the near future.
Accounting issues related to the Sanofi deal remain undecided. MannKind and its auditors have not finalized how the upfront payment and milestones will be treated, other than to say they will be recognized once the Company is booking revenue and earnings are estimable. Treatment of MannKind’s share of losses generated by Afrezza’s rollout is another issue awaiting resolution. Hence, we are not providing 2015 estimates presently.
Sanofi has given hints about its marketing plans, though more information may be forthcoming on November 20th when it will hold a New Medicines seminar. We believe Afrezza’s launch will consist of two parts, one promoting it based on the benefits of prandial insulin for early-stage type 2 diabetics most of whom will probably require only a single dose of the current formulation. The other part of the marketing campaign will likely promote Afrezza and Sanofi’s new basal insulin, Toujeo®, for diabetics who are more advanced. A price break may even be offered to encourage use of both drugs.
We think investor interest in MannKind shares will rise in the months ahead as Afrezza begins to penetrate the diabetes market. However, the Company’s income statement may not be very informative initially, depending on how the upfront fee, milestone payments, and proportionate share of Afrezza losses are treated. MNKD stock remains on our BUY list.
|
|
|
|
Post by joeypotsandpans on Nov 4, 2014 10:09:18 GMT -5
Josh is just plain laughable at this point www.streetinsider.com/Analyst+PT+Change/MannKind+%28MNKD%29+RiskReward+More+Interesting+Ahead+of+Afrezza+Launch%2C+Piper+Jaffray+Says/9972290.html?si_client=intbroMannKind (MNKD) Risk/Reward More Interesting Ahead of Afrezza Launch, Piper Jaffray SaysPiper Jaffray analyst Joshua Schimmer lowered his price target on Neutral-rated MannKind (NASDAQ: MNKD) to $7.00 (from $9.50) following in-line Q3 results but notes as the Afrezza launch nears "things are getting more interesting." Schimmer commented, "Affrezza has yet to launch and won't be a relevant contributor until 2015. Operating expenses are falling as expected and will continue to decline meaningfully as SNY picks up its share of commercialization. Accounting for the milestone payment from SNY was adjusted to reflect uncertainty of timing of Afrezza franchise profitability, but this is a non-cash consideration and therefore not impactful. We are revising our estimates to reflect challenges in the diabetes market, but admit that recent share decline is starting to make the MNKD risk reward more interesting." The firm bumped FY 2014 EPS from ($0.51) to ($0.44) and FY 2015 EPS from ($0.30) to ($0.28). For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here. Shares of MannKind closed at $5.92 yesterday. |
|
|
|
Post by kc on Nov 4, 2014 10:53:56 GMT -5
Only time will tell what upgrades we might see in the next 90 days. I know that one of the questions came yesterday from Adnan Butt of RBC Capital. He follows MannKind so hopefully he will issue a reaffirmation of his past positive comments. Below is a chart as of today of some the current Analyst ratings. Attachment Deleted |
|
|
|
Post by joeypotsandpans on Nov 4, 2014 11:19:40 GMT -5
www.streetinsider.com/Analyst+EPS+Change/BofAMerrill+Lynch+Remains+Cautious+on+MannKind+%28MNKD%29+Ahead+of+Afrezza+Launch/9972561.html?si_client=intbroBofA/Merrill Lynch analyst Steve Byrne reiterated an Underperform rating and $4 price target on Mannkind (NASDAQ: MNKD) following Q3 earnings and ahead of the Afrezza launch. The analyst notes that on the call the company highlighted that Sanofi is fully committed to the launch of Afrezza in spite of its CEO termination and weakness in basal insulin pricing. "While the company provided limited details on commercial plans (some reps will have Afrezza as primary detail), we expect additional details at Sanofi’s business update in Cambridge on November 20th," Byrne commented. "We note that Sanofi is a very strong partner in the diabetes space, but we remain cautious about Afrezza’s penetration in the increasingly competitive diabetes market." The firm adjusted FY 2014 EPS from ($0.06) to ($0.53), FY 2015 EPS from ($0.32) to ($0.25) and FY 2016 EPS from ($0.03) to ($0.10).
For an analyst ratings summary and ratings history on MannKind click here. For more ratings news on MannKind click here. Shares of MannKind closed at $5.92 yesterday. We've known which side they're on LOLOL! Seriously, Matt doesn't even know how they're going to book the milestone payments...how does he even attempt to project 2016 full year EPS, complete joke these guys
|
|
